Abaloparatide

Mechanism (as reported)

Research described abaloparatide as a selective activator of the parathyroid hormone type 1 receptor. (PMIDs: 27533157)

Key findings (each cites a source)

• In a phase 3, double-blind randomized clinical trial (ACTIVE) in postmenopausal women with osteoporosis, new morphometric vertebral fractures occurred less frequently in the abaloparatide groups than in placebo over 18 months, and bone mineral density increases were greater with abaloparatide than placebo. (PMIDs: 27533157) [PMID 27533157]
• In the same ACTIVE trial, the Kaplan-Meier estimated event rate for nonvertebral fracture was lower with abaloparatide than placebo. (PMIDs: 27533157) [PMID 27533157]
• In ACTIVE, incidence of hypercalcemia was lower with abaloparatide (3.4%) than with teriparatide (6.4%). (PMIDs: 27533157) [PMID 27533157]
• A living systematic review and network meta-analysis reported that abaloparatide (and teriparatide) reduced clinical and radiographic vertebral fractures, while increasing withdrawals due to adverse events (WAEs). (PMIDs: 36592455) [PMID 36592455]
• The living systematic review and network meta-analysis reported that abaloparatide, teriparatide, and sequential romosozumab, then alendronate, may be more effective than bisphosphonates in reducing clinical fractures for 17 to 24 months in older postmenopausal females at very high fracture risk. (PMIDs: 36592455) [PMID 36592455]
• The provided sources describe abaloparatide as a synthetic peptide analog of PTHrP used to manage/treat osteoporosis, and note that FDA approval is for postmenopausal women at high risk of fracture due to osteoporosis. (PMIDs: 36512663) [PMID 36512663]
• An overview article described that teriparatide and abaloparatide target the parathyroid hormone-1 receptor and are given by daily subcutaneous injection for up to 2 years (as described in the source). (PMIDs: 35279261) [PMID 35279261]
• Clinical guidance documents in the provided sources state that multiple pharmacologic therapies are capable of reducing fracture rates in postmenopausal women at risk, with acceptable risk-benefit and safety profiles (general statement about pharmacologic options). (PMIDs: 30907953) [PMID 30907953]